WULAN PANDUWI MELASARI, 051515153010 (2017) PENGARUH PEMBERIAN ATORVASTATIN TERHADAP PERUBAHAN PROFIL LIPID DAN PETANDA INFLAMASI TNF-α PADA PASIEN DIABETES DENGAN DISLIPIDEMIA (Penelitian dilakukan di Poliklinik Ilmu Penyakit Dalam RSU Haji Surabaya). Thesis thesis, Universitas Airlangga.
|
Text (ABSTRAK)
ABSTRACT .pdf Download (2MB) | Preview |
|
Text (FULLTEXT)
TFK 09-18 Mel p.pdf Restricted to Registered users only until 9 March 2021. Download (2MB) | Request a copy |
Abstract
Background – Diabetics patients have 2 to 4 times increased risk of cardiovascular disease compared with non-diabetics. TNF-α is a proinflammatory cytokine that can be used to determine the risk of atherosclerosis complications triggered by inflammation in diabetes. Statins are a class of HMG CoA reductase inhibitors that inhibit cholesterol biosynthesis and have pleioropic effects that inhibit the release of inflammatory cytokines like TNF-α and stabilize atherosclerotic plaques. Objectives – This study aims to determine the effect of atorvastatin 20 mg/day for 30 days in reducing the lipid profile and TNF-α inflammatory markers in patients with diabetes dyslipidemia. Methods – Diabetes patient with dyslipidemia who included the inclusion criteria in this observational prospective cohorts studies treated with atorvastatin for 30 days (n = 19). The efficacy of statin therapy was measured by lipid profiles (LDL, TG, HDL, and total cholesterol) and TNF-α. Result – The results of the study showed that atorvastatin decreased 40.55% of LDL levels, 15.34% of TG levels, and 30.70% oftotal cholesterol levels which statistically significant (p<0.05). As for HDL, there is an increase of 6.06% but statistically nonsignificant (p>0.05). TNF-α levels increased by 11.30% which statistically non-significant (p> 0.05). Conclusion – The use of atorvastatin 20 mg for 30 days gave reduction in LDL, TG, and total cholesterol and increased in HDL. Atorvastatin doesn’t have a reducing effect on TNF-α. There was no correlation between lipid profile changes with TNF-α changes.
Item Type: | Thesis (Thesis) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Additional Information: | KKB KK-2 TFK.09/18 Mel p | ||||||||||||
Uncontrolled Keywords: | Atorvastatin, lipid, TNF-α, diabetes, dyslipidemia | ||||||||||||
Subjects: | R Medicine > RC Internal medicine > RC31-1245 Internal medicine R Medicine > RS Pharmacy and materia medica |
||||||||||||
Divisions: | 05. Fakultas Farmasi > Farmasi Klinis | ||||||||||||
Creators: |
|
||||||||||||
Contributors: |
|
||||||||||||
Depositing User: | sugiati | ||||||||||||
Date Deposited: | 08 Mar 2018 20:56 | ||||||||||||
Last Modified: | 08 Mar 2018 20:56 | ||||||||||||
URI: | http://repository.unair.ac.id/id/eprint/70522 | ||||||||||||
Sosial Share: | |||||||||||||
Actions (login required)
View Item |